The effect of oestradiol valerate and cyclic oestradiol valerate/DL-norgestrel on calcium metabolism.
Fasting plasma and urinary calcium and urinary hydroxyproline are known to rise at the menopause, reflecting increased bone resorption. Oestradiol valerate and cyclic oestradiol valerate/DL-norgestrel are shown to reduce this evidence of increased bone loss. It is concluded that these preparations will be effective in preventing post-menopausal loss of bone.
D002118:Calcium / Q000378:metabolism*; D004958:Estradiol / Q000494:pharmacology*; D005260:Female; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D008593:Menopause / Q000187:drug effects; D009644:Norgestrel / Q000494:pharmacology*
D009644:Norgestrel; D004958:Estradiol; D006909:Hydroxyproline; D002118:Calcium